Continent with an app - from research to implementation of mobile apps for self-treatment of urinary leakage

Purpose and goal:

Urinary leakage is a common problem, every fourth woman and every eighth man have problems. The Tät® app is based on self-treatment of urinary leakage and is one of the very few apps that has been evaluated in research regarding effectiveness and health economics. The goal for eContinence AB is to further develop the app and be able to provide it to as many people as possible in a safe and secure way as a CE-marked product.

Expected results and effects:

The app is now further developed and launched as a class I medical device via Google and Apple as a Basic and Premium app respectively. It is now available in Sweden, Norway, Denmark, Finland, Great Britain, Spain, Germany and Austria. It is available in 8 languages. Currently, there are approximately 70,000 people who have the app installed. We now have a scalable product for a global market and are working further to develop the app as a licensed product in collaboration with health companies.

Approach and implementation:

The quality management system and technical documentation have been updated with support of consultants and workshop trainings. The app could be CE-marked within the EU in 2022 and later also in Norway and Great Britain. The Tät® app has been further developed and launched commercially in 2022. We continue our work on a version of the app aimed for healthcare companies.